These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 26843024)
1. Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer. Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M Int J Clin Oncol; 2016 Aug; 21(4):783-790. PubMed ID: 26843024 [TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of dynamic conformal arc irradiation combined with neoadjuvant hormonal therapy in Japanese patients with T1c-T2N0M0 prostate cancer: case series study. Ikeda I; Mizowaki T; Norihisa Y; Takayama K; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O; Hiraoka M Jpn J Clin Oncol; 2014 Feb; 44(2):180-5. PubMed ID: 24379210 [TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer. Mizowaki T; Takayama K; Norihisa Y; Ogura M; Kamba T; Inoue T; Shimizu Y; Kamoto T; Ogawa O; Hiraoka M Int J Clin Oncol; 2012 Dec; 17(6):562-8. PubMed ID: 21968911 [TBL] [Abstract][Full Text] [Related]
4. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209 [TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer. Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133 [TBL] [Abstract][Full Text] [Related]
6. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation. Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T Int J Clin Oncol; 2019 Oct; 24(10):1247-1255. PubMed ID: 31152322 [TBL] [Abstract][Full Text] [Related]
7. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation. Baumann BC; Baumann JC; Christodouleas JP; Soffen E Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422 [TBL] [Abstract][Full Text] [Related]
8. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832 [TBL] [Abstract][Full Text] [Related]
9. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome. Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210 [TBL] [Abstract][Full Text] [Related]
10. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful? Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V Tumori; 2004; 90(2):201-7. PubMed ID: 15237583 [TBL] [Abstract][Full Text] [Related]
11. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era? Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052 [TBL] [Abstract][Full Text] [Related]
12. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505 [TBL] [Abstract][Full Text] [Related]
14. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01. Mydin AR; Dunne MT; Finn MA; Armstrong JG Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):101-8. PubMed ID: 22658512 [TBL] [Abstract][Full Text] [Related]
15. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer. Vuky J; Pham HT; Warren S; Douglass E; Badiozamani K; Madsen B; Hsi A; Song G Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e609-15. PubMed ID: 22208976 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer. Sakamoto M; Mizowaki T; Mitsumori M; Takayama K; Sasai K; Norihisa Y; Kamoto T; Nakamura E; Ogawa O; Hiraoka M Int J Clin Oncol; 2010 Dec; 15(6):571-7. PubMed ID: 20652347 [TBL] [Abstract][Full Text] [Related]
18. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Stock RG; Stone NN Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181 [TBL] [Abstract][Full Text] [Related]
19. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy. Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931 [TBL] [Abstract][Full Text] [Related]
20. Optimal duration of androgen deprivation in combination with radiation therapy for Japanese men with high-risk prostate cancer. Takaha N; Okihara K; Kamoi K; Kimura Y; Yamada T; Kawauchi A; Kobayashi K; Yamazaki H; Nishimura T; Miki T Urol Int; 2011; 87(1):28-34. PubMed ID: 21701133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]